What this topic covers
Subpart 3B (Perform Quality Assurance/Improvement) of the Content Outline effective June 1, 2022: quality assurance programs, medication errors, compounding complaints, adverse event reporting, continuing education and the competence of pharmacy personnel. These are original practice notes, not documents of the California State Board of Pharmacy or PSI, based on law in force on January 1, 2027; time limits, thresholds and quantities can change with each year's legislation. Nothing here is medical advice.
Quality assurance program
- Required program: every pharmacy documents medication errors attributable to the pharmacy or its personnel (B&P Code section 4125(a)).
- Confidentiality: records are peer review documents not subject to discovery, but the Board may review them (B&P Code section 4125(b)).
Medication errors
- Review: all medication errors discovered are subject to a quality assurance review (16 CCR section 1711(d)).
- Telling the patient: as soon as possible, inform the patient and the prescriber when the drug was administered or therapy was delayed (16 CCR section 1711(c)(2) and (c)(3)).
- Record contents: date, location and participants; pertinent data; findings; recommended changes (16 CCR section 1711(e)).
- Purpose: to advance error prevention by finding system or process failures, not to discipline (16 CCR section 1711(e)).
- Retention: retrievable for at least one year (16 CCR section 1711(f); as of January 1, 2027; check for later changes).
- Automated systems: review sent to the Board within 30 days of completion (16 CCR section 1711(f); as of January 1, 2027; check for later changes).
Self-assessment and compounding quality
- Self-assessment: kept on file for three years (16 CCR section 1715(d); as of January 1, 2027; check for later changes).
- Compounding complaint: review started within 72 hours; written notice to the Board within 96 hours (16 CCR section 1735.12(b) and (c); as of January 1, 2027; check for later changes).
Outcomes and adverse events
- MUE outcome: an outcome indicator measures the patient result, such as resolved infections (theory: medication use evaluation).
- Root cause analysis: looks for causes and system failures, not fault (theory: root cause analysis).
- Adverse events: suspected serious events are reported to the FDA's MedWatch program (theory: adverse event reporting).
Continuing education
- Hours: 30 hours of approved continuing education in the prior 24 months (B&P Code section 4231(b); 16 CCR section 1732.5(a); as of January 1, 2027; check for later changes).
- Audit failure: the Board cancels the active license and issues an inactive one (B&P Code section 4231(e)).
- Addiction course: Schedule II prescribers complete at least one hour once every four years (16 CCR section 1732.5(d); as of January 1, 2027; check for later changes).
Personnel competence
- Technician trainee: enrolled in a qualifying pharmacy technician training program (B&P Code section 4038(b)).
- Certification: Pharmacy Technician Certification Board and National Healthcareer Association programs (16 CCR section 1793.65; approval valid through June 30, 2027; check for later changes).
- Sterile supervisor: after a failed aseptic evaluation, supervision for no more than 30 days (16 CCR section 1736.2(d); as of January 1, 2027; check for later changes).
- Technician checking: orders previously reviewed by a pharmacist, under the pharmacist-in-charge (16 CCR section 1793.8).
- Designated persons: background check and signed policies; no technician license (16 CCR section 1714.3).
- Interns: the supervising pharmacist is responsible for the intern's activities (16 CCR section 1726(a)).
Sample questions (5)
1. Which of the following must every pharmacy establish under Business and Professions Code section 4125?
- A drug utilization review committee
- A quality assurance program for errors
- An external audit of pharmacy safety
- A peer review panel of pharmacists
Business and Professions Code section 4125(a) requires every pharmacy to “establish a quality assurance program” that documents medication errors attributable, in whole or in part, to the pharmacy or its personnel. The section names no drug utilization review committee and no external audit. A peer review panel is not required either: subdivision (b) only gives the program's records the status of peer review documents.
2. A pharmacist at Sierra Valley Pharmacy discovers a medication error. Within what period must the pharmacy commence an investigation of it under 16 CCR section 1711(d)?
- Within 1 business day of discovery
- Within 2 business days of discovery
- Within 3 business days of discovery
- Within 5 business days of discovery
As of January 1, 2027, 16 CCR section 1711(d) requires the investigation to “commence as soon as is reasonably possible, but no later than 2 business days” from the date the medication error is discovered. One business day is shorter than the outer limit the regulation sets, and three or five business days go past that limit.
3. After a dispensing error, the pharmacist-in-charge of Juniper Flats Pharmacy completes the quality assurance review and creates its record. Under 16 CCR section 1711(f), for how long must that record remain immediately retrievable in the pharmacy?
- For at least 1 year from its creation
- For at least 2 years from its creation
- For at least 3 years from its creation
- For at least 5 years from its creation
As of January 1, 2027, the record described in 16 CCR section 1711(e) must be “immediately retrievable in the pharmacy for at least one year from the date the record was created” under section 1711(f). A three-year period governs other documents, such as the self-assessment that 16 CCR section 1715(d) keeps on file, while two and five years are periods that neither section sets for these records.
4. When must the pharmacist-in-charge complete the routine self-assessment of a pharmacy under 16 CCR section 1715(a)?
- Before Jan. 1 of each odd-numbered year
- Before July 1 of each calendar year
- Before July 1 of each even-numbered year
- Before July 1 of each odd-numbered year
As of January 1, 2027, 16 CCR section 1715(a) provides that the assessment “shall be performed before July 1 of every odd-numbered year”. The cycle is every two years, not annual, and it falls in odd-numbered years, not even-numbered ones. January 1 is not the deadline in the text.
5. A pharmacist-in-charge completes the pharmacy's self-assessment on March 2, 2027. How long must the completed self-assessment be kept on file in the pharmacy under 16 CCR section 1715(d)?
- 1 year after it is performed
- 2 years after it is performed
- 3 years after it is performed
- 5 years after it is performed
As of January 1, 2027, 16 CCR section 1715(d) says each self-assessment is “kept on file in the pharmacy for three years after it is performed”, and the signed original must be readily available to the Board during an inspection. One year is the retrievability period for quality assurance review records in 16 CCR section 1711(f). Two and five years appear in neither section.